Stocks · News reference
Fractyl Health is sharpening its focus on its lead product candidate, Revita, while discontinuing its Rejuva gene therapy program and reducing its workforce by approximately 45%.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Fractyl Health released findings from a market survey indicating significant patient interest in a one-time procedural approach for weight maintenance following GLP-1 therapy.
Fractyl Health has appointed Harith Rajagopalan as president following the retirement of Jay Caplan.